An honor to participate in the study! A major breakthrough in NPC treatment!
Results of a phase 2 trial of ipilimumab and nivolumab in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
nature.com/articles/s41467-0…
#CancerResearch @natrescancer @DrGopalIyer
67
Hsiang-Fong Kao, MD PhD retweeted
#Lenvatinib plus #eribulin is safe, has manageable side effects and promising efficacy in patients with advanced #leiomyosarcoma and#liposarcoma. Study by Chen et al shows that combining antiangiogenic agents and #chemotherapy is feasible.
https://teapawt.net/t.co/u46rGupGnt @saxotomy
Hsiang-Fong Kao, MD PhD retweeted
Nasopharyngeal carcinoma (NPC) is a type of head & neck cancer linked to EBV infection & prevalent in east & southeast Asia. In Annals of Oncology, results of the KEYNOTE-122 randomized, ph III trial of Pembrolizumab vs chemo in platinum-pretreated NPC
annalsofoncology.org/article…





